NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price & News

$8.17

+0.06 (+0.74%)

(As of 09/26/2023 ET)

Compare

Today's Range: $8.06
▼
$8.39
50-Day Range: $8.11
▼
$12.27
52-Week Range: $4.07
▼
$12.43

Volume: 1.55 million shs
Average Volume: 1.61 million shs
Market Capitalization: $1.17 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.33

Aurinia Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 63.2% Upside
$13.33 Price Target
Short Interest: Healthy
9.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.05
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.58) to ($0.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

672nd out of 963 stocks

Pharmaceutical Preparations Industry

308th out of 451 stocks

3.4

Analyst's Opinion

Consensus Rating
Aurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.33, Aurinia Pharmaceuticals has a forecasted upside of 63.2% from its current price of $8.17.
Amount of Analyst Coverage
Aurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
9.73% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.
Change versus previous month
Short interest in Aurinia Pharmaceuticals has recently decreased by 16.41%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aurinia Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Aurinia Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AUPH.

2.8

News and Social Media Coverage

News Sentiment
Aurinia Pharmaceuticals has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 8 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 39.64% of the stock of Aurinia Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.58) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aurinia Pharmaceuticals is -16.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aurinia Pharmaceuticals is -16.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aurinia Pharmaceuticals has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

AUPH Price History

30 days | 90 days | 365 days | Advanced Chart

AUPH Stock News Headlines

September 27, 2023 | seekingalpha.com

Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade)

September 24, 2023 | americanbankingnews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Reaffirmed by HC Wainwright

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 21, 2023 | finance.yahoo.com

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

September 18, 2023 | msn.com

Why Aurinia Pharmaceuticals Stock Is Slumping Today

September 18, 2023 | finance.yahoo.com

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

September 11, 2023 | finance.yahoo.com

Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation

September 6, 2023 | finance.yahoo.com

Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

August 21, 2023 | finance.yahoo.com

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

August 8, 2023 | msn.com

HC Wainwright & Co. Maintains Aurinia Pharmaceuticals (AUPH) Buy Recommendation

August 5, 2023 | markets.businessinsider.com

Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital

August 3, 2023 | msn.com

Aurinia spikes on Q2 earnings beat, guidance raise

August 3, 2023 | finance.yahoo.com

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

July 27, 2023 | finance.yahoo.com

Institutions own 42% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares but individual investors control 56% of the company

July 25, 2023 | finance.yahoo.com

Nasdaq EM Asia Utilities Large

July 20, 2023 | finance.yahoo.com

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

July 19, 2023 | finance.yahoo.com

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

July 18, 2023 | seekingalpha.com

Aurinia: Strategic Alternatives Could Go Either Way For Stakeholders

July 11, 2023 | finance.yahoo.com

Aurinia Pharmaceuticals Stock Shows Rising Relative Strength

July 6, 2023 | msn.com

Cantor Fitzgerald Reiterates Aurinia Pharmaceuticals (AUPH) Overweight Recommendation

July 3, 2023 | finance.yahoo.com

Aurinia (AUPH) Up on Paving the Way for a Potential Buyout

July 3, 2023 | finance.yahoo.com

Aurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?

June 30, 2023 | msn.com

Aurinia Pharma could see high $20s to low $30s a share in takeover - analyst

June 30, 2023 | msn.com

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

June 30, 2023 | marketwatch.com

Aurinia Pharma Shares Rise 9% As Company Explores Strategic Alternatives

June 30, 2023 | 247wallst.com

Aurinia Pharmaceuticals Share Surge Shows Investor Support for Board Reboot, Strategic Review

See More Headlines

Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Company Calendar

Last Earnings: 8/03/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AUPH
CUSIP: N/A
CIK: 1600620
Web: www.auriniapharma.com
Phone: 250-708-4272
Fax: 250-744-2498
Employees: 300
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $13.33
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +63.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,180,000.00
Net Margins: -45.42%
Pretax Margin: -44.42%
Return on Equity: -18.05%
Return on Assets: -14.85%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 6.75
Quick Ratio: 6.21

Sales & Book Value

Annual Sales: $134.03 million
Price / Sales: 8.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.85 per share
Price / Book: 2.87

Miscellaneous

Outstanding Shares: 143,420,000
Free Float: 137,255,000
Market Cap: $1.17 billion
Optionable: Optionable
Beta: 1.24

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Peter S. Greenleaf M.B.A. (Age 53)
Pres, CEO & Director
Comp: $1.34M

Mr. Joseph M. Miller CPA (Age 49)
Chief Financial Officer
Comp: $791.92k

Mr. Matthew Maxwell Donley M.B.A. (Age 54)
Exec. VP of Operations & Strategy
Comp: $811.82k

Mr. Stephen P. Robertson (Age 41)
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
Comp: $739.68k

Dr. Volker Knappertz D.Sc. (Age 58)
M.D., Exec. VP of R&D
Comp: $742.85k

Mr. James Archie Harrell Jr. (Age 53)
Head of Investor Relations

Mr. Fran Lynch
VP of Sales

Mr. Michael R. Martin (Age 51)
Chief Bus. Officer

Ms. Sue Evans
Sr. VP of Global Regulatory Affairs

Mr. Scott Habig (Age 63)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AUPH Stock - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.
What is Aurinia Pharmaceuticals' stock price forecast for 2023?: 4 brokers have issued 1 year price targets for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $12.00 to $15.00. On average, they anticipate the company's stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.
How have AUPH shares performed in 2023?: Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH stock has increased by 89.1% and is now trading at $8.17.
View the best growth stocks for 2023 here.
When is Aurinia Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AUPH earnings forecast.
How were Aurinia Pharmaceuticals' earnings last quarter?: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.12. The biotechnology company earned $41.49 million during the quarter, compared to analysts' expectations of $37.90 million. Aurinia Pharmaceuticals had a negative net margin of 45.42% and a negative trailing twelve-month return on equity of 18.05%. The firm's revenue for the quarter was up 47.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.25) EPS.
What ETFs hold Aurinia Pharmaceuticals' stock?: ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).
What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings?: Aurinia Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$160.00 million, compared to the consensus revenue estimate of $154.35 million.

What other stocks do shareholders of Aurinia Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).
What is Aurinia Pharmaceuticals' stock symbol?: Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."
Who are Aurinia Pharmaceuticals' major shareholders?: Aurinia Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.81%), State Street Corp (1.84%), Goldman Sachs Group Inc. (1.22%), Renaissance Technologies LLC (1.07%), Geode Capital Management LLC (0.98%) and Northern Trust Corp (0.70%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.
How do I buy shares of Aurinia Pharmaceuticals?: Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aurinia Pharmaceuticals' stock price today?: One share of AUPH stock can currently be purchased for approximately $8.17.
How much money does Aurinia Pharmaceuticals make?: Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.17 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.
How many employees does Aurinia Pharmaceuticals have?: The company employs 300 workers across the globe.
How can I contact Aurinia Pharmaceuticals?: Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.

This page (NASDAQ:AUPH) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial